Bullets, balance, or both: medicalisation in HIV treatment.

References 1 Auton F. The advertising of pharmaceuticals direct to consumers: a critical review of the literature and debate. Int J Adver 2004; 23: 1–5. 2 Hone F, Benson R. DTC: European style. Pharm Exec 2004; 24: 96–102. 3 Kravitz RL, Epstein RM, Feldman MD, et al. Infl uence of patients’ requests for direct-to-consumer advertised antidepressants: a randomized controlled trial. JAMA 2005; 293: 1995–2002. 4 Angell M. The truth about the drug companies: how they deceive us and what to do about it. New York: Random House, 2004: 83. 5 Hollon M. Direct-to-consumer advertising: a haphazard approach to health promotion. JAMA 2005; 293: 2030–33. 6 Weissman JS, Blumenthal D, Silk AJ, Zapert K, Newman M, Leitman R. Consumers’ reports on the health eff ects of direct-to-consumer drug advertising. Health Aff (Millwood). Published online Feb 26, 2003. DOI:10.1377/hlthaff .w3.82. 7 Metzl JM. Prozac on the couch: prescribing gender in the era of wonder drugs. Durham: Duke; 2003. 8 Aikin KJ. Direct-to-consumer advertising of prescription drugs: physician survey. Jan 13, 2003. http://www.fda.gov/cder/ddmac/ globalsummit2003/sld001.htm (accessed Feb 13, 2007). 9 Alexander-Banys B. Pharmaceutical company advertising practices: call to arms. J Pediatr Health Care 2002, 16: 49–50. 10 Metzl JM, Angel J. Assessing the impact of SSRI antidepressants on popular notions of women’s depressive illness. Soc Sci Med 2004; 58: 577–84.